Jiaqi Fan, MD

Durvalumab with or without Bevacizumab as Adjuvant Therapy for Patients with Hepatocellular Carcinoma at Risk of Recurrence After Curative Therapy: EMERALD-2

Purpose: Hepatic resection and ablation are standard of care for patients with hepatocellular carcinoma (HCC), but although potentially curative, the risk of recurrence is high (44%–79% a...

Joong-Won Park ;

Peter R. Galle , MD, PhD;

Riccardo Lencioni , MD;

Jennifer J. Knox ;

Jiaqi Fan , MD;

Ann-Lii Cheng , MD, PhD;

Shethah Morgan ;

Jian Zhou , MD, PhD;

Sean Cleary ;

Norihiro Kokudo ;

10/21/2019

CIO 2020-22 Durvalumab±Bevacizumab As Adjuvant Therapy In HCC At Risk Of Recurrence After Curative Therapy: EMERALD-2

Peter R. Galle , MD, PhD;

Riccardo Lencioni , MD;

Philip He ;

Jennifer J. Knox ;

Shethah Morgan ;

Jiaqi Fan , MD;

Gordon Cohen ;

Sean Cleary ;

Ann-Lii Cheng , MD, PhD;

Norihiro Kokudo ;

Jian Zhou , MD, PhD;

Joong-Won Park ;

07/23/2021

Clinical Images

The First Two Cases of Long-Term Outcomes After Transcatheter Aortic Valve Replacement in Patients With Quadricuspid Aortic Valve

10/01/2021

Jian Wang , MM, MD, PhD;

Dao Zhou , MD;

Jiaqi Fan , MD;

Xianbao Liu , MD, PhD;

A 79-year-old man was admitted to the hospital for severe aortic stenosis and moderate aortic regurgitation and a type B QAV was found on CT in an 86-year-old man.

A 79-year-old man was admitted...

10/01/2021

Journal of Invasive Cardiology